Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development

Stephen J. Thomas, Joachim Hombach, Alan Barrett

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Dengue is a re-emerging arboviral disease of great public health importance. Limited understanding of protective immune responses against dengue has hampered advancement of dengue vaccine candidates. Demonstrating an immunological correlate of protection has been limited to associating quantitative neutralizing antibody titers with clinical outcomes following infection. There have been a number of studies investigating the role of cell mediated immunity (CMI) in natural infections and these have demonstrated roles in both virus clearance and potentiating disease. Vaccine developers have extended the exploratory study of CMI in natural infection to the study of dengue vaccine recipients. Primary infections and monovalent vaccine administration generates dengue type-specific T-cell responses. Secondary infection, vaccination of flavivirus primed individuals, or administration of multivalent vaccine candidates results in broad, cross-reactive T-cell responses, similar to the broadening of antibody patterns. However, the precise function of CMI in protection or disease pathology remains ill-defined and, at present, there is no evidence to suggest that CMI can be utilized as a correlate of protection. Nonetheless, the study of CMI in natural infection and following vaccine administration should continue in an attempt to improve the understanding of dengue immunopathology, vaccine candidate immunogenicity, and potential correlates of protection.

Original languageEnglish (US)
Pages (from-to)355-368
Number of pages14
JournalVaccine
Volume27
Issue number3
DOIs
StatePublished - Jan 14 2009

Fingerprint

Dengue Vaccines
dengue
Dengue
vaccine development
Cellular Immunity
cell-mediated immunity
Referral and Consultation
vaccines
Vaccines
Infection
infection
T-Lymphocytes
Flavivirus
T-lymphocytes
immune response
Neutralizing Antibodies
Coinfection
immunopathology
emerging diseases
Vaccination

Keywords

  • CMI
  • Dengue
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. / Thomas, Stephen J.; Hombach, Joachim; Barrett, Alan.

In: Vaccine, Vol. 27, No. 3, 14.01.2009, p. 355-368.

Research output: Contribution to journalArticle

Thomas, Stephen J. ; Hombach, Joachim ; Barrett, Alan. / Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development. In: Vaccine. 2009 ; Vol. 27, No. 3. pp. 355-368.
@article{aa6475e2a35644f9b076f0ae1a6362d6,
title = "Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development",
abstract = "Dengue is a re-emerging arboviral disease of great public health importance. Limited understanding of protective immune responses against dengue has hampered advancement of dengue vaccine candidates. Demonstrating an immunological correlate of protection has been limited to associating quantitative neutralizing antibody titers with clinical outcomes following infection. There have been a number of studies investigating the role of cell mediated immunity (CMI) in natural infections and these have demonstrated roles in both virus clearance and potentiating disease. Vaccine developers have extended the exploratory study of CMI in natural infection to the study of dengue vaccine recipients. Primary infections and monovalent vaccine administration generates dengue type-specific T-cell responses. Secondary infection, vaccination of flavivirus primed individuals, or administration of multivalent vaccine candidates results in broad, cross-reactive T-cell responses, similar to the broadening of antibody patterns. However, the precise function of CMI in protection or disease pathology remains ill-defined and, at present, there is no evidence to suggest that CMI can be utilized as a correlate of protection. Nonetheless, the study of CMI in natural infection and following vaccine administration should continue in an attempt to improve the understanding of dengue immunopathology, vaccine candidate immunogenicity, and potential correlates of protection.",
keywords = "CMI, Dengue, Vaccine",
author = "Thomas, {Stephen J.} and Joachim Hombach and Alan Barrett",
year = "2009",
month = "1",
day = "14",
doi = "10.1016/j.vaccine.2008.10.086",
language = "English (US)",
volume = "27",
pages = "355--368",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Scientific consultation on cell mediated immunity (CMI) in dengue and dengue vaccine development

AU - Thomas, Stephen J.

AU - Hombach, Joachim

AU - Barrett, Alan

PY - 2009/1/14

Y1 - 2009/1/14

N2 - Dengue is a re-emerging arboviral disease of great public health importance. Limited understanding of protective immune responses against dengue has hampered advancement of dengue vaccine candidates. Demonstrating an immunological correlate of protection has been limited to associating quantitative neutralizing antibody titers with clinical outcomes following infection. There have been a number of studies investigating the role of cell mediated immunity (CMI) in natural infections and these have demonstrated roles in both virus clearance and potentiating disease. Vaccine developers have extended the exploratory study of CMI in natural infection to the study of dengue vaccine recipients. Primary infections and monovalent vaccine administration generates dengue type-specific T-cell responses. Secondary infection, vaccination of flavivirus primed individuals, or administration of multivalent vaccine candidates results in broad, cross-reactive T-cell responses, similar to the broadening of antibody patterns. However, the precise function of CMI in protection or disease pathology remains ill-defined and, at present, there is no evidence to suggest that CMI can be utilized as a correlate of protection. Nonetheless, the study of CMI in natural infection and following vaccine administration should continue in an attempt to improve the understanding of dengue immunopathology, vaccine candidate immunogenicity, and potential correlates of protection.

AB - Dengue is a re-emerging arboviral disease of great public health importance. Limited understanding of protective immune responses against dengue has hampered advancement of dengue vaccine candidates. Demonstrating an immunological correlate of protection has been limited to associating quantitative neutralizing antibody titers with clinical outcomes following infection. There have been a number of studies investigating the role of cell mediated immunity (CMI) in natural infections and these have demonstrated roles in both virus clearance and potentiating disease. Vaccine developers have extended the exploratory study of CMI in natural infection to the study of dengue vaccine recipients. Primary infections and monovalent vaccine administration generates dengue type-specific T-cell responses. Secondary infection, vaccination of flavivirus primed individuals, or administration of multivalent vaccine candidates results in broad, cross-reactive T-cell responses, similar to the broadening of antibody patterns. However, the precise function of CMI in protection or disease pathology remains ill-defined and, at present, there is no evidence to suggest that CMI can be utilized as a correlate of protection. Nonetheless, the study of CMI in natural infection and following vaccine administration should continue in an attempt to improve the understanding of dengue immunopathology, vaccine candidate immunogenicity, and potential correlates of protection.

KW - CMI

KW - Dengue

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=57649176766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57649176766&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2008.10.086

DO - 10.1016/j.vaccine.2008.10.086

M3 - Article

C2 - 19022321

AN - SCOPUS:57649176766

VL - 27

SP - 355

EP - 368

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 3

ER -